Natasha Fay Thoren - 20 May 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Legal Officer
Issuer ticker: XFOR
Reported as of: 20 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2025, 16:21:11 UTC
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Natasha Fay Thoren filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 03 Jul 2025.

Key facts

This page summarizes Natasha Fay Thoren's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 16:21.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002070977 Primary reporting owner

Thoren Natasha Fay

Relationship: Chief Legal Officer
Address: C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON
Signature: /s/ Adam S. Mostafa, attorney-in-fact
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +3,333
Change %: +54%
Price: $0.000000
Shares after: 9,462
Date: 20 May 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

Footnote F2

The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025.